Shares of Adma Biologics Inc. (NASDAQ:ADMA) dropped 2.9% on Thursday . The company traded as low as $5.34 and last traded at $5.34, with a volume of 93,770 shares trading hands. The stock had previously closed at $5.50.

ADMA has been the topic of a number of analyst reports. Maxim Group cut their price target on Adma Biologics from $24.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, July 25th. Raymond James Financial Inc. cut Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 1st.

The firm’s market cap is $67.65 million. The firm’s 50 day moving average price is $6.38 and its 200-day moving average price is $6.38.

Adma Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Friday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.11. On average, equities analysts predict that Adma Biologics Inc. will post ($1.83) EPS for the current year.

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.